EuCC Meeting Hotel Bildungszentrum 21, Missionsstr. 21, CH-4055 Basel, Tel. +41 (0) ,

Similar documents
DKTK Local Retreat Partner Site Freiburg

3 rd Berlin Cancer Retreat - Agenda

Cancer Biology Course. Invasion and Metastasis

Promising Bifunctional Agents in Immuno- Oncology: A Roundtable Discussion with the Experts

mirna Dr. S Hosseini-Asl

Tumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School

CRC 992 Symposium on Medical Epigenetics 2018

Fundamental research on breast cancer in Belgium. Rosita Winkler

DFG. DFG Hinterzartener Kreis für Krebsforschung. From Molecular Mechanisms to Cancer Therapy. May 2-5, 2013 Villa La Collina Cadenabbia (Co), Italy

The use of diagnostic FFPE material in cancer epidemiology research

Invited Journal: Nature Medicine. Sponsors: Thermo Fisher Novocure Merck. Venue: Spanish National Cancer Research Centre CNIO Auditorium Madrid, Spain

DFG. DFG Hinterzartener Kreis für Krebsforschung. From Molecular Mechanisms to Targeted Cancer Therapy

LYON. FRANCE NOVEMBER / 2013 TRANSLATIONAL RESEARCH IN CHRONIC VIRAL HEPATITIS - BRIDGING BASIC SCIENCE AND CLINICAL RESEARCH

State of the Art Symposium

Frontiers in PREVENTION. Research November 7-10, 2010 Pennsylvania Convention Center Philadelphia, PA

PDX MODELS IN CLINICAL ONCOLOGY AND CANCER PRECISION MEDICINE 3-5 OCTOBER Seminar-Hotel Rigi am See Weggis Switzerland

Contents 1 The Windows of Susceptibility to Breast Cancer 2 The So Called Pre-Neoplastic Lesions and Carcinoma In Situ

OMICS Journals are welcoming Submissions

Paul Murray University of Birmingham

Type of file: PDF Size of file: 0 KB Title of file for HTML: Supplementary Information Description: Supplementary Figures

VIII Curso Internacional del PIRRECV. Some molecular mechanisms of cancer

3 rd course on BREAST CANCER: FROM CLINICS TO BIOLOGY June 19-23, 2017 Institut Curie - Training Unit - International Course

Transformation of Normal HMECs (Human Mammary Epithelial Cells) into Metastatic Breast Cancer Cells: Introduction - The Broad Picture:

Maximizing the Potential of Population-Based Cancer Registries to Inform Cancer Research

Infos:

Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development MicroTek Training Center Washington, DC October 17 19, 2018

ESMO-ESO Course on Medical Oncology for Medical Students Educational Programme July 2016, Valencia, Spain

Roche Investor Relations ASCO Planner 2017

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment

18 th Annual Meeting Saturday, January 23, 2016 University of Lausanne

Neoplasia 18 lecture 6. Dr Heyam Awad MD, FRCPath

B. Mark Evers, MD Director, Markey Cancer Center University of Kentucky

SESSION 1: IMMUNE CHECKPOINTS: MECHANISMS AND THERAPEUTIC OPPORTUNITIES Grand Ballroom I/II

SCIENTIFIC TIMETABLE SIOP 2015

Table S1: Analysis of Notch gene rearrangements in triple negative breast cancer subtypes

Bayer to Present New Data on Advancing Oncology Portfolio. New Preclinical and Early Clinical Data Evaluating Innovative Compounds in Drug Development

Genetics and Cancer Ch 20

2016 CRUK Lung Cancer Centre of Excellence Student/Postdoc Winter Workshop Programme

PI3K Background. The SignalRx R & D pipeline is shown below followed by a brief description of each program:

CCN1: A NOVEL TARGET FOR PANCREATIC CANCER. Andrew Leask.

GBS 2018 Frankfurt Congress Program

Immune surveillance hypothesis (Macfarlane Burnet, 1950s)

Lecture 1: Carcinogenesis

ROLE OF TGF-BETA SIGNALING IN PIK3CA-

BASIC MECHANISM OF TUMOR IMMUNE SUPPRESSION

The Hallmarks of Cancer

Karyotype analysis reveals transloction of chromosome 22 to 9 in CML chronic myelogenous leukemia has fusion protein Bcr-Abl

Cancer Biology Dynamical Cell Systems

2018: HORIZONS OF CANCER BIOLOGY AND THERAPY

1.The metastatic cascade. 2.Pathologic features of metastasis. 3.Therapeutic ramifications

Dicerna Pharmaceuticals Overview. Delivering RNAi-Based Breakthrough Therapies

Ludwig Presence at 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates

Pathology of Inflammatory Breast Cancer (IBC) A rare tumor

Cancer. The fundamental defect is. unregulated cell division. Properties of Cancerous Cells. Causes of Cancer. Altered growth and proliferation

Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development One Washington Circle Hotel, Washington, DC October 19-21, 2016

Cancer Diagnosis and Treatment August 02-03, 2018 Oslo, Norway

Molecular Pathology of Renal Cell Carcinoma: An Update

Lecture 11. Section C (Week 3): Understanding Diseases of the Immune System

Cell Polarity and Cancer

Cancer genetics

Scientific Meeting Report. Prof. C. Sessa. ESMO Publishing Working Group 8 th International Symposium on Targeted Anticancer Therapies TAT 2010

Course Organizers: Neal Copeland, Ph.D., The Houston Methodist Research Institute Nancy Jenkins, Ph.D., The Houston Methodist Research Institute

Lecture 8 Neoplasia II. Dr. Nabila Hamdi MD, PhD

1. The metastatic cascade. 3. Pathologic features of metastasis. 4. Therapeutic ramifications. Which malignant cells will metastasize?

Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development One Washington Circle Hotel, Washington, DC October 25-27, 2017

Therapeutic targeting neuraminidase-1 in multi-stage of tumorigenesis

Cancer Genetics. What is Cancer? Cancer Classification. Medical Genetics. Uncontrolled growth of cells. Not all tumors are cancerous

Emerging" hallmarks of cancer, a. Reprogramming of energy metabolism b. Evasion of the immune system, Enabling characteristics, a.

Cancer. The fundamental defect is. unregulated cell division. Properties of Cancerous Cells. Causes of Cancer. Altered growth and proliferation

31 st Annual Meeting Chicago 2018 Preliminary Program

Revolutionizing the Treatment of Cancer

Novel MOAs and targets for cancer drug development What s hot off the presses?

3 Pancreatic Cancer Forum

TUESDAY, 18th OCTOBER, 2016 / DAY -2

Revolutionizing the Treatment of Cancer

Cancer immunity and immunotherapy. General principles

Tumor Biology and Experimental Therapeutics Program

BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

Highlights from AACR 2015: The Emerging Potential of Immunotherapeutic Approaches in Non-Small Cell Lung Cancer

Neoplasia 2018 lecture 4. Dr Heyam Awad MD, FRCPath

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015

Molecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy

Inflammatory Cells and Metastasis

Does EMT Contribute to Radiation Resistance in Human Breast Cancer?

Berlin. Title: Industry Satellite Symposium. Vienna. Title: Industry Satellite Symposium. Exhibition area. Title: Welcome reception

International workshop NO-CANCER 2017 From Cancerogenesis to Therapy: new paradigms, new opportunities

TUESDAY, 18th OCTOBER, 2016 / DAY -2. THE SPENCER HOTEL Hall A Hall B (St. Lukes Hospital)

OMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors

microrna Presented for: Presented by: Date:

Revolutionizing the Treatment of Cancer

Revisione Oral Abstracts

Summary of Research and Writing Activities in Oncology

OncoMir Library Cancer Type Target Gene

CHAPTER VII CONCLUDING REMARKS AND FUTURE DIRECTION. Androgen deprivation therapy is the most used treatment of de novo or recurrent

CELL BIOLOGY - CLUTCH CH CANCER.

PRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019

Faculty of Pathology 37th Annual Symposium & Annual General Meeting. Thursday 7 th & Friday 8 th February 2019 Approved for up 8 CPD credits

Faculty of Pathology 37th Annual Symposium & Annual General Meeting. Thursday 7 th & Friday 8 th February 2019 Approved for up to 8 CPD credits

International Society of Breast Pathology. Immune Targeting in Breast Cancer. USCAP 2017 Annual Meeting

Transcription:

EuCC Meeting 2017 Date: 12th May 2017 Venue: Hotel Bildungszentrum 21, Missionsstr. 21, CH-4055 Basel, Tel. +41 (0)61 260 21 21, http://www.bildungszentrum-21.ch Morning Session: Focus Cancer Immunotherapy 8.45-8.55 Welcome (Alfred Zippelius, Basel; Justus Duyster, Freiburg Session 1: Chair Heinz Läubli, Basel; Gertraud Orend, Strasbourg 8.55-9.35 Sacha Rothschild Abishek Kashyap, Basel 9.35-10.15 Olivier Adotevi Christophe Borge, Strasbourg 10.15 10.50 Coffee Break Chair Alfred Zippelius, Basel; Michael Luebbert, Freiburg 10.50 11.30 Nimitha Mathew Nikolas von Bubnoff, Freiburg 11.30 11.45 Miriam Ronsdorf, University Basel: European Campus 11.45 12.45 Keynote Lecture: Prof. Pedro Romero, Lausanne 12.45 14.00 Lunch, Poster Viewing

Afternoon Session: Basic and Clinical Cancer Research Session 1: Cancer Immunology / Phase I Chair: Primo Schär, Basel; Jocelyn Ceraline, Strasbourg 14.00 14.15 Devadarssen Murdamoothoo, Strasbourg Role of the Tenascin-C in modulating the immune microenvironment of breast cancer 14.15 14.30 Eleonora Cremonesi, Basel Gut microbiota modulate T cell trafficking into human colorectal cancer 14.30 14.45 Franziska Uhlenbrock, Basel A novel tumor targeted 4-1BB agonist amplifies intratumoral T cell effector functions in fresh human tumor lesions from cancer patients 14.45 15.00 Vincent Pretre, Basel First in Human, Phase I, Dose Escalation Pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mtor Inhibitor PQR309 in patients with advanced solid tumors 15.00 15.05 Florence Schaffner, Strasbourg Crossborder cancer research investigator database project 15.05 15.30 Coffee break Session 2: Tumor Biology Chair: Momo Bentires-Alj, Basel; Melanie Börries, Freiburg 15.30 15.45 Mathilde Baranger, Strasbourg The atypical cadherin MUCDHL is decreased in the cancer stem cell molecular subtype of colon tumors and inhibits β-catenin signaling in a non-classical way 15.45 16.00 Jerry H. Fuady, Freiburg The role of PBRM1 mutation in epigenetic dysregulation and clear cell renal cell carcinoma metastasis 16.00 16.15 Faiza Noreen, Basel Genetics talks to epigenetics

16.15 16.30 M. Boerries, Freiburg Meta-analysis of cohort data for detection of early biomarkers for pancreatic cancer 16.30 16.45 N. Rimmer, Basel Experimental strategy to target the expression and endogenous glycosylation of E-cadherin in an EMT ovarian cancer cell line model 16.45 17.00 Jesus Duque Afonso, Freiburg Comparative studies of B cell precursor ALL pathogenesis using a conditional transgenic mouse model reveals signaling remodeling by E2A-PBX1 17.00 Paul-Basset Award for the top abstract presentation and end of Symposium

Posters: 1. S. Hussung, Freiburg Pancreatic Cancer 3D Organoids: a Co-clinical Platform for Translational Research and Ex vivo Drug Testing 2. S. Ehrenfeld, Freiburg Functional identification of novel molecular dependencies in Cyclin D1- driven lymphoma 3. M. Trefny, Basel An in vitro Model for T cell Dysfunction in Human Tumors 4. V. Mele, Basel Membrane-bound TGF-beta on tumor-associated mesenchymal stemlike cells initiates epithelial-to-mesenchymal transition and promotes colorectal cancer dissemination 5. M. Diepenbruck, Basel mir-1199-5p and Zeb1: a novel double-negative feedback loop coordinating EMT and tumor metastasis 6. S. Beyes, Freiburg The proto-oncogene MYB is a directly repressed target gene of the EMT master regulator SNAIL1 7. L. D Amico, Basel Dynamics of the global tumor immunome upon treatment with a novel anti-her2 anthracycline based antibody drug conjugate in breast cancer 8. M. Hirschfeld, Freiburg Diagnostic potential of micro RNAs expression profiles in breast and gynecologic cancer 9. M.G. Muraro, Basel Perfusion-based bioreactor culture of primary cancer tissue maintains tumor microenvironment complexity and allow in-vitro testing of immune blockade therapy

10. V. Governa, Basel The interplay between neutrophils and CD8+ T cells improves survival in human colorectal cancer 11. F. Jacob, Basel Dissecting the tumor-promoting role of bisecting GlcNAc on N- glycoproteins in epithelial ovarian cancer 12. L. Keilholz, Freiburg The chromatin remodeler Smarca4 regulates c-myc in B cells 13. M. Stanczak, Basel Upregulation of self-associated molecular patterns and Siglec receptors on T cells facilitate cancer immune evasion 14. G. Orend, Strasbourg Janus role of Tenascin-C in tumor angiogenesis 15. Alejandro Gomez-Auli, Freiburg Lysosomal cathepsin B regulates the antitumoral glycoprotein CREG1 16. Anaïs Nicol, Strasbourg Expression of a p53 family member correlates with the expression of DAMPs and an improved prognostic in a subgroup of HPV-induced cancers of the oropharynx 17. Gilles Riegel, Strasbourg Activation of Immune cell death and ER stress by organometallic compounds to facilitate immunotherapy in gastric cancer 18. S. Vorbach Freiburg Enhanced expression of the Sphingosine-1-Phosphate-Receptor-3 causes Acute Myelogenous Leukemia in mice